Adherium (ASX:ADR), a digital health company focussed on improving patient medication adherence and health outcomes, says it has manufactured and sold it’s one-hundred thousandth Smartinhaler.
The outcome represents a significant commercial milestone for the company. The Smartinhalers have now been sold and supplied in more than 40 countries.
Smartinhalers are electronic sensors that attach to a patient’s prescription inhaled medicine. Once attached, the Smartinhaler automatically tracks medication usage and reminds the patient to take their medication as prescribed. They also automatically upload the electronic medication usage to a smartphone app where the patient or caregiver can review their usage, and to a web portal for population health management.
According to the company, the Smartinhaler has been shown to improve patient outcomes, including reducing hospitalisation in children. They have been used in numerous clinical programs around the world, resulting in over 70 peer reviewed journal articles in the world’s leading respiratory journals such as Thorax, and The Lancet Respiratory Medicine.
"It is one thing to design smartinhalers, but a whole different matter to manufacture and sell this number of devices," said Adherium CEO Arik Anderson.